NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

I referred to Outlook because they received UK and EMA approval and the stock price did not move that much.
For the market, it is important that a nonrevenue biotech clearly indicates that it will, within a reasonable timeframe, start earning positive cash flow.
This could be achieved by selling its just-approved medication or by a upfront license deal.

Unfortunately at the last ASM Powers stated that there is no license deal in sight and she said that they still need to hire consultants for negotiations with NICE.
It would have been better if Powers had not shared this information. Now the market may respond less enthusiastically to the UK approval news.
NWBO management does tend to kick all speculative elements from the stock price.